MVX-ONCO-1 in Patients With Solid Tumor

Phase 1Active Not RecruitingNCT02193503

Maxivax SA34 enrolled

Overview

The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who are not or not any longer amenable to any standard therapy of their tumour disease.

Endpoints: Primary: To assess safety parameters including adverse and serious adverse events (incidence, causality, severity), local and systemic tolerance to the administered study treatment, changes in laboratory values and vital signs in patients with solid tumor; Secondary: to measure some tumor responses in using imaging technique, serological tumor markers, immune monitoring and metabolic monitoring.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumor Cancer

Interventions

TreatmentOTHER

Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients aged 18 years and older with advanced metastatic cancer in progression of various sites \[Carcinoma of lung (either small cell or non-small cell), colon, breast, pancreas (exocrine or endocrine), stomach, oesophagus, head\&neck, thyroid, kidney, bladder, prostate, ovary, uterus (cervix or corpus); Sarcoma of soft tissue, bone, uterus, melanoma; primary brain tumor\] where all recognized treatment are exhausted or not feasible. * Life expectancy: estimate of at least 4 months. Exclusion Criteria: * Have participated in any other investigational study or received an experimental therapeutic procedure considered to interfere with the study in the 4 preceding weeks. * Have received any chemotherapy treatment in the 4 preceding weeks. * Serious concomitant health condition such as organ transplant requiring immunosuppressive drugs, severe psychiatric disorders. * History of second cancer within the last 2 years with the exception of basal cell carcinoma of skin and localized cervical carcinoma treated with curative intent. * Patient with a systemic disease other than cancer, that is not controlled by usual medication. * Therapeutic anticoagulation with coumarine or continues iv heparin. Low-molecular weight heparin (LMWH) is permitted as long as treatment can be withheld several hours prior to subcutaneous implantation. * Positive HIV-1, HIV-2, HTLV-1, HTLV-2, hepatitis B surface antigen, or hepatitis C antibody.

Locations (1)

Hopitaux Universitaires de Genève - HUG

Geneva, Canton of Geneva, Switzerland

Outcomes

Primary Outcomes

Number of patients with Adverse Events and/or Serious Adverse Events

Adverse events will be followed carefully at each clinic visit by the Investigator, to determine their incidence, causality and severity.

Time frame: 18 weeks

Secondary Outcomes

Delayed type hypersensitivity reactions, Induction of a specific CD8 response

immune monitoring

Time frame: 18 weeks

imaging and metabolic monitoring

Time frame: 18 weeks

tumor size

document of tumor number, sites, size of lesions

Time frame: 18 weeks

tumor pain

intensity, site, frequency of pain, use of analgesics

Time frame: 18 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.